Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study

被引：7

作者：

Budde, L. Elizabeth ^{[1
]}

Olszewski, Adam J. ^{[2
]}

Assouline, Sarit ^{[3
]}

Lossos, Izidore S. ^{[4
]}

Diefenbach, Catherine ^{[5
]}

Kamdar, Manali ^{[6
]}

Ghosh, Nilanjan ^{[7
]}

Modi, Dipenkumar ^{[8
]}

Sabry, Waleed ^{[9
]}

Naik, Seema ^{[10
]}

Mehta, Amitkumar ^{[11
]}

Nakhoda, Shazia K. ^{[12
]}

Smith, Stephen D. ^{[13
]}

Dorritie, Kathleen ^{[14
]}

Jia, Ting ^{[15
]}

Pham, Song ^{[16
]}

Huw, Ling-Yuh ^{[17
]}

Wu, Hao ^{[17
]}

To, Iris ^{[17
]}

Wei, Michael C. ^{[17
]}

Chavez, Julio C. ^{[18
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA

[3] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[6] Univ Colorado, Aurora, CO USA

[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[8] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[9] Univ Saskatchewan, Saskatoon Canc Ctr, Coll Med, Saskatoon, SK, Canada

[10] Penn State Canc Inst, Hershey, PA USA

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] Fox Chase Canc Ctr, Philadelphia, PA USA

[13] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[14] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[15] Roche China Holding Ltd, Shanghai, Peoples R China

[16] F Hoffmann Roche Ltd, Basel, Switzerland

[17] Genentech Inc, San Francisco, CA USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[11] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Preliminary Phase Ib/II Data supports the controllable Safety and encouraging Efficacy in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL)
Hutchings, M.
Sureda, A.
Terol, M. J.
Bosch, F.
Corradini, P.
Stauffer, Larsen T.
Rueda, Dominguez A.
Panchal, A.
Bottos, A.
Carlile, D.
Wang, Y.
de L'Etang, Filezac A.
Tandon, M.
Sellam, G.
Gritti, G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 54 - 54
[12] Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study
Wang, Michael L.
Assouline, Sarit
Kamdar, Manali
Ghosh, Nilanjan
Naik, Seema
Nakhoda, Shazia K.
Chavez, Julio C.
Jia, Ting
Pham, Song
Huw, Ling-Yuh
Jing, Jing
Ead, Wahib
To, Iris
Batlevi, Connie Lee
Wei, Michael C.
Budde, L. Elizabeth
BLOOD, 2023, 142
[13] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
Sehn, Laurie H.
Matasar, Matthew J.
Flowers, Christopher R.
Kamdar, Manali
McMillan, Andrew K.
Hertzberg, Mark
Assouline, Sarit
Kim, Tae Min
Kim, Won Seog
Ozcan, Muhit
Croft, Brandon
Hirata, Jamie
Cheng, Ji
Ku, Grace
Herrera, Alex F.
BLOOD, 2019, 134
[14] Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL).
Budde, L. Elizabeth
Ghosh, Nilanjan
Chavez, Julio C.
Lossos, Izidore S.
Mehta, Amitkumar
Dorritie, Kathleen Anne
Kamdar, Manali K.
Negricea, Raluca
Pham, Song
Hristopoulos, Maria
Huw, Ling-Yuh
O'Hear, Carol Elaine
Oki, Yasuhiro
To, Iris
Diefenbach, Catherine S. Magid
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[15] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Hutchings, Martin
Sureda, Anna
Terol, Maria Jose
Albareda, Francesc Bosch
Corradini, Paolo
Larsen, Thomas Stauffer
Dominguez, Antonio Rueda
Panchal, Anesh
Bottos, Alessia
Carlile, David
Wang, Yanjie
De L'Etang, Audrey Filezac
Tandon, Maneesh
Sellam, Gila
Gritti, Giuseppe
BLOOD, 2021, 138
[16] Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Budde, Elizabeth
Ghosh, Nilanjan
Chavez, Julio
Lossos, Izidore S.
Mehta, Amitkumar
Dorritie, Kathleen
Kamdar, Manali
Negricea, Raluca
Song Pham
Hristopoulos, Maria
Huw, Ling-Yuh
O'Hear, Carol
Oki, Yasuhiro
To, Iris
Diefenbach, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S393 - S394
[17] Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Izquierdo, Antonia Rodriguez
Martin, Eva Maria Donato
Garcia-Sancho, Alejandro Martin
Sandoval-Sus, Jose David
Tilly, Herve
Vandenberghe, Elizabeth
Hirata, Jamie
Choudhry, Priya
Chang, Yi Meng
Musick, Lisa
McMillan, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[18] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
Terui, Yasuhito
Rai, Shinya
Izutsu, Koji
Yamaguchi, Motoko
Takizawa, Jun
Kuroda, Junya
Ishikawa, Takayuki
Kato, Koji
Suehiro, Youko
Fukuhara, Noriko
Ohmine, Ken
Goto, Hideki
Yamamoto, Kazuhito
Kanemura, Nobuhiro
Ueda, Yasunori
Ishizawa, Kenichi
Kumagai, Kyoya
Kawasaki, Atsuko
Saito, Tomohisa
Hashizume, Misato
Shibayama, Hirohiko
CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
[19] Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
Sehn, Laurie H.
Hertzberg, Mark
Opat, Stephen
Herrera, Alex F.
Assouline, Sarit
Flowers, Christopher R.
Kim, Tae Min
McMillan, Andrew K.
Ozcan, Muhit
Safar, Violaine
Salles, Gilles
Hirata, Jamie
Yang, Annie
Musick, Lisa
Matasar, Matthew J.
BLOOD, 2022, 140 : 9464 - 9467
[20] Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial
Diefenbach, Catherine
Kahl, Brad S.
Banerjee, Lalita
McMillan, Andrew K.
Miall, Fiona
Briones, Javier
Cordoba, Raul
Hirata, Jamie
Chang, YiMeng
Musick, Lisa
Abrisqueta, Pau
BLOOD, 2019, 134

← 1 2 3 4 5 →